An analysis led by a researcher at UT Southwestern Medical Center, which looked at costs for patients with Hepatocellular carcinoma in the first year after diagnosis, found that median Medicare payments exceeded $65,000 and out-of-pocket costs were more than $10,000—significantly more than costs for patients with cirrhosis alone.
Updated results from the HIMALAYA phase III trial showed AstraZeneca’s Imfinzi (durvalumab) plus Imjudo (tremelimumab-actl) demonstrated a sustained, clinically meaningful overall survival benefit at five years for patients with unresectable hepatocellular carcinoma who had not received prior systemic therapy and were not eligible for localized treatment.
